Coeptis Therapeutics (NASDAQ:ZSQR) Shares Down 12.1% – Time to Sell?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s share price fell 12.1% during mid-day trading on Monday . The stock traded as low as $14.53 and last traded at $14.70. Approximately 115,379 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 128,262 shares. The stock had previously closed at $16.73.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics presently has an average rating of “Sell”.

Coeptis Therapeutics Trading Down 12.9%

The firm has a market capitalization of $749.34 million, a price-to-earnings ratio of -5.78 and a beta of -0.22. The business’s 50-day moving average price is $12.28 and its 200 day moving average price is $12.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics in the fourth quarter worth about $259,000. State Street Corp raised its position in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. Geode Capital Management LLC lifted its stake in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the period. Finally, Yorkville Advisors Global LP bought a new position in shares of Coeptis Therapeutics in the third quarter valued at approximately $140,000. 13.88% of the stock is currently owned by institutional investors.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.